Qiagen NV (Qiagen NV) Common Stock

: $3 Mil (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

Qiagen NV's quarterly common stock stayed the same from Jun. 2023 ($3 Mil) to Sep. 2023 ($3 Mil) and stayed the same from Sep. 2023 ($3 Mil) to Dec. 2023 ($3 Mil).

Qiagen NV's annual common stock stayed the same from Dec. 2021 ($3 Mil) to Dec. 2022 ($3 Mil) and stayed the same from Dec. 2022 ($3 Mil) to Dec. 2023 ($3 Mil).

Qiagen NV Common Stock Historical Data

The historical data trend for Qiagen NV's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qiagen NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

2.70

Qiagen NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock																2.70	2.70	2.70	2.70	2.70

Qiagen NV Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Qiagen NV (Qiagen NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Qiagen NV (NYSE:QGEN) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

1QGEN:Italy QIAd:UK 0RLT:UK QIA:Germany QIA:Germany QIA:Germany QIA:Germany QGEN:Austria

Address

Hulsterweg 82, Venlo, LI, NLD, 5912 PL

Website

https://www.qiagen.com

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (over 45% of 2022 sales), followed by EMEA (nearly 35%), and Asia-Pacific (nearly 20%).

Executives